UnderValued Bulletin: Sky High Profits With CBIS

cbisCannabis Science, Inc. takes advantage of its unique understanding of metabolic processes to provide innovative treatment options for unmet medical needs.

Cannabis use has an extensive history dating back thousands of years, and currently there are thousands of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate.

The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment of multiple critical ailments from cancer and infections to age-related illnesses.

CS-S/BCC1 is in preparation to enter phase I clinical trials within one to two year. This product is formulated for topical administration to be tested in phase I study, with an indication for skin cancer.

CS-TATI1 is in preclinical development with the indication for infectious disease. Consistent with data published in March by researchers at the Mount Sinai School of Medicine found that cannabinoids inhibit TAT induced migration to TAT via cannabinoid 2 receptors (CB2) which has potential applications in HIV and other infectious diseases.

In 2013, Cannabis Science submitted patent application N2010968 in Europe entitled “Composition for the Treatment of Neurobehavioral Disorders.” The subject of the patent is development of cannabinoid-based formulations to treat a variety of neurobehavioral disorders, such as attention deficit hyperactivity disorder (ADHD) and anxiety. The first formulation in the series of neurobehavioral disorder-targeted products is the pre-clinical development and use of the invention in food products through a licensing agreement with partner company, ENDOCAN Corporation, Inc. And Cannabis Science will move forward at the same time with pharmaceutical grade development.

Basis & Philosophy

Cannabis plants have extensive history of medical and agricultural use dating back thousands of years.

To date hundreds of natural constituents covering several chemical classes have been isolated and identified from the Cannabis plant.

Some key phytocannabinoids are:

  • tetrahydrocannabinol (THC)
  • cannabidiol (CBD)
  • cannabigerol (CBG)
  • cannabichromene (CBC)
  • cannabinol (CBN)

These cannabinoids belong to the chemical class of terpenophenolics, of which 85 have been uniquely identified in cannabis, including the most psychoactive cannabinoid, THC. Some applications of cannabinoids have been well established in peer-reviewed literature such as for alleviating nausea and stimulating the appetite for people with AIDS and cancer. Other well-known uses include easing chronic pain and reducing muscle spasms associated with multiple sclerosis and spinal cord injuries.

The pharmacology of THC has been widely studied, while many other identified cannabinoids are still poorly characterized pharmacologically and biologically, with new activities for cannabinoids consistently being discovered.

Cannabis Science is developing novel cannabis based approaches to treat the world’s most deadly illnesses. We learn from patients about the healing properties of cannabis medicines. Our immediate focus is the development of cutting edge cancer treatments.

The Company’s future endeavors include infectious illnesses, neurobehavioral disorders including attention deficit disorder, post-traumatic stress disorder; and an application of the anti-inflammatory activities of cannabis in the management of age-related illnesses.

The endocannabinoid system possessed by all vertebrates regulates all body systems and maintains homeostasis. As such, the mechanisms of phytocannabinoids’ biological impact are multidimensional.

While concentrating on our core activities of discovering and developing treatments that will make a meaningful difference in patients’ lives, we remain mindful that we have other responsibilities to the clinicians who utilize our drugs, health authorities around the world, our shareholders, our employees, and the communities in which we live and work. We continually strive to improve our corporate responsibility standards and activities, implementing comprehensive ethical standards and undertaking patient and community progressive initiatives.

These principles reflect the mission of Cannabis Science to provide innovative therapeutics for unmet medical needs.

As the industry leader, Cannabis Science consults and leads other emerging businesses that Cannabis Science believes has a preferred business model, one which will mature into a key business model in the future. Our consulting is on the entire “seed to sale” process with a focus on bio-pharmaceutical development.

Cannabis Science is one of the longest standing companies in the cannabis business.
We feel that the correct way is to look at the industry from a bio-pharmaceutical standpoint, in a manner that allows cannabinoid-based products to modulate the endocannabinoid system to treat multiple conditions. Scientifically, we know this is the beginning of one of the greatest expansions of medicine and industry we will ever experience in our lifetime.

See what Cannabis Science has in the works and their progress. These programs will change the lives of many people of all ages, shapes, and sizes, with a variety of illnesses that cannabinoid-based medications can target. These illnesses include cancer, HIV/AIDS, arthritis, chronic pain, and a myriad of others. Click here to see what’s coming down the pipeline!
Read More +

Cannabis sativa is one of the most widely used plants for both recreational and medicinal purposes. To date a total of 525 natural constituents covering several chemical classes have been isolated and identified from Cannabis sativa. The cannabinoids belong to the chemical class of terpenophenolics, of which 85 have been uniquely identified in cannabis, including the most psychoactive cannabinoid, tetrahydrocannabinol commonly referred to as THC.

The most common natural plant cannabinoids (phytocannabinoids) are: THC, cannabidiol (CBD), cannabigerol (CBG), cannabichromene (CBC), and cannabinol (CBN). Several of the identified cannabinoids are both chemically and pharmacologically poorly characterized; however, the pharmacology of THC has been widely studied, and it is regarded as the main psychoactive constituent of cannabis.

There are three general types of cannabinoids:
1. Phytocannabinoids, that occur uniquely in the cannabis plant.
2. Endogenous cannabinoids produced naturally in many animal species including humans.
3. Synthetic cannabinoids compounds produced in a laboratory. Forms of synthetic THC are available by prescription in a number of countries, including the US. In the US, marketed as Marinol®.

Phytocannabinoids, also called natural cannabinoids, herbal cannabinoids, and classical cannabinoids, are only known to occur naturally in significant quantity in the cannabis plant. They are concentrated in a viscous resin that is produced in glandular structures known as trichomes, and are most prevalent in the flowers of the female plants.

Cannabinoid receptors in the human body were not discovered until 1988. CB1 receptors are found throughout the body and are the most prevalent neurotransmitter system in the brain, specifically in the basal ganglia and in the limbic system, including the hippocampus. They are also found in the cerebellum and in both male and female reproductive systems.

CB2 receptors are found most exclusively in the immune system, with the greatest density in the spleen. CB2 receptors appear to be responsible for the anti-inflammatory and possibly other therapeutic effects of cannabis. CB2 receptors appear in any tissue when there is pathology.
The endocannabinoid system refers to a group of neuromodulators and receptors involved in a variety of physiological processes including appetite, pain sensation, mood, and memory. The system is named for endocannabinoids, the endogenous lipids that bind cannabinoid receptors.

Science increasingly recognizes the role that endo-cannabinoids play in major life functions in the human body. Cannabinoids act as a bio regulatory mechanism, which explains why they have been recommended as a treatment for many diseases and ailments in anecdotal reports and scientific literature. Common prescribed ailments include: Pain, arthritic conditions, migraine headaches, anxiety, epileptic seizures, insomnia, loss of appetite, GERD (chronic heartburn), nausea, glaucoma, AIDS wasting syndrome, depression, bipolar disorder (particularly depression-manic-normal), multiple sclerosis, menstrual cramps, Parkinson’s, trigeminal neuralgia (tic douloureux), high blood pressure, irritable bowel syndrome, and bladder incontinence.

Pipeline – Cannabis Science’s focus is HIV/AIDS (CS-TAT1-I) and Cancer (CS-S/BCC-1)


Data published in March by researchers at the Mount Sinai School of Medicine found that cannabinoids inhibit TAT induced migration to TAT via cannabinoid 2 receptors (CB2).

Cannabis Science’s development of CS-TATI-1 will be targeted to both newly diagnosed and treatment-experienced patients with drug-resistant HIV strains, as well as those intolerant of currently available therapies. Cannabis Science will be pursuing a wide range of NIH based Federal Research Programs such as RO1s, PO1s and SBIRs which exist to support preclinical development of target validation and proof of concept studies. Cannabis Science will be pursing implementation of these studies through collaborations with leading scientific institutions. Cannabis Science will also be pursuing other clinical research collaborations including the AIDS Clinical Trials Groups (ACTG), the Canadian AIDS Trial Network (CATN) and the European AIDS Trial Network (EATN).

Our product is a whole plant extract, formulated for topical administration as a Phase I product, then to be potentially investigated as an oral administration for systemic delivery.

Since 2011, we have seen apparent success in 4 skin cancer patients who have self-administered CS-S/BCC-1 –cannabinoid based extracts topically to their basal and squamous cell carcinomas. These patients have experienced shrinking and apparent eradication of their skin cancer lesions, backed by positive reports from their doctors. With these results, Cannabis Science is confident it can begin programs for over the counter (OTC) and prescription drug markets. The company is consulting with a team of FDA specialists to plan for a pre-IND meeting with the agency with the goal of creating a road map leading to an IND application.


CBIS Key Company Management
Dr. Robert Melamede, Ph.D. – President and Director
Dr. Melamede has a Ph.D. in Molecular Biology and Biochemistry from the City University of New York. He retired as Chairman of the Biology Department at University of Colorado, Colorado Springs in 2005, where he continues to teach. Dr. Melamede is recognized as a leading authority on the therapeutic uses of cannabinoids, and has authored or co-authored dozens of papers on a wide variety of scientific subjects. Dr. Melamede also serves on the Scientific Advisory Board of Americans for Safe Access, the Unconventional Foundation for Autism, The World Aids Institute, Board Tim Brown Foundation (The Berlin Patient), Phoenix Tears Foundation, and regularly consults with professional and lay persons around the world regarding cannabis and health issues. He also served as a director of Newellink Inc, a Colorado-based company specializing in cancer research.

Dr. Dorothy Bray, Ph.D. – Chief Executive Officer and Director
Dr. Dorothy Bray, Ph.D., Former Global Director of HIV Research and Senior Clinical Program Head of HIV and Opportunistic Infections for GlaxoSmithKline. Dr. Bray held various positions of responsibility at GlaxoSmithKline.
Dr. Bray is the President and owner of ImmunoClin as well as a member of the Scientific Staff and the Head of Scientific Business Development of The Medical Research Council Clinical Trials Unit. As well, Dr. Bray has authored or co-authored multiple publications and has an extensive network of collaborations and contacts with pharmaceutical companies, governments, and non- government organizations in key developed and developing markets; European Commission Scientific Expert.


  • May 21, 2014 Cannabis Science Inc. To Oversee Research For NewColombia Resources
  • May 20, 2014 Innovation Fuels New Cannabis Based Skin Care Medicines – NEWC’s Pharmaceutical Partner in Discussions with City of Medellin
  • May 15, 2014 Cannabis Based Medicines Gain Traction as Research & Development Ramp up – Company Looks to Develop Topical Cannabis Medicine to Treat Skin Cancer
  • May 15, 2014 New Colombia Resources Inc. Enters Into a Collaboration Agreement With Farmatech S.A. for Research and Development of Topical Cannabis Based Medicines in Colombia
  • May 9, 2014 Research & Development Kick Into High Gear For Cannabis Based Medicine – New Collaboration Agreement For Development of Cannabis Based Skin Cancer Medicine
  • May 9, 2014 New Colombia Resources Inc. Enters into a Collaboration Agreement with the Phoenix Tears Foundation for Research and Development of a Cannabis Based Medicine to Treat Skin Cancer in Colombia.
  • May 1, 2014 Cannabis Science Supports Patients Out of Time’s Eighth National Clinical Conference on Cannabis Therapeutics held May 8-10, 2014 in Portland, Oregon
  • Apr 30, 2014 Cannabis Science Inc. Signs Agreement With MEDIWIET to Conduct Clinical Observational Study in the Netherlands
  • Apr 28, 2014 Cannabis Science, Inc. (CBIS) Commends Dr. Sanjay Gupta on His On-Going Contribution to Learning and Educating Regarding the Efficacy of Medical Cannabis for Patients In Need
  • Apr 25, 2014 Lexaria Announces Managers of Ontario Facility and First Phase Production Plans

CBIS Headlines finance.yahoo.com/q/h?s=CBIS+Headlines 

 penny stocks

With a chart that’s clearly bottoming out and so many releases no-doubt yet to come, we feel now is an ideal time to begin an investment into Cannabis Science (CBIS) and issue a conservative target of a dollar per share by Jan 2016 is not unreasonable. Keep this on your radar! 

Tags: , , , , , , , , , , , , , ,

No comments yet.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: